GET DAILY SIGNALSCingulate (CING) Stock: Analyst Target at $21 Implies +280% Upside
Key Takeaways
- The central target of $21 is the rounded arithmetic mean of the five current analyst price targets used, averaging about $21.20, against a recent share price near $5.53.
- Reaching $21 would require a roughly 280% rise, a very large move for a clinical-stage biopharmaceutical company.
- Analyst targets are unusually wide, spanning approximately $8 to $44, reflecting deep disagreement about the company's clinical and commercial outlook.
- The strongest supporting factor is the lead candidate CTx-1301 in Phase 3 trials for ADHD (attention-deficit/hyperactivity disorder), a large commercial market.
- The biggest risks are negative cash flow, a need for additional capital, no product revenue, and the binary outcome of late-stage clinical trials.
- For more on Major News, Today's Price Move, the Forecast, and Earnings, explore these dedicated pages for updated context on this ticker.
- Readers can also explore Trending AI Robots for AI-driven scanning and trading ideas across the market.
Analyst Price Targets and Consensus View
Cingulate Inc. (CING) is a clinical-stage biopharmaceutical company based in Kansas City, Kansas, developing treatments for ADHD and anxiety using its Precision Timed Release drug-delivery platform. It is covered by a small group of analysts whose views are exceptionally wide-ranging. Across five analyst targets, the calculated mean is roughly $21.20, which rounds to a $21 central target. The approximate range runs from $8 to $44, underscoring how divergent the estimates are. Verified individual targets include Roth MKM's $9 (August 2026), Maxim Group's $8 (August 2026), H.C. Wainwright's $20 (May 2026), and Ascendiant Capital, which cut its target from $58 to $55 in April 2026. Aggregators such as S&P Global data through Investing.com and StockAnalysis report a consensus "Strong Buy" rating with a mean near $21. The gap between the lowest and highest targets reflects different assumptions about the probability that CTx-1301 (dexmethylphenidate) clears Phase 3 trials, wins regulatory approval, and captures market share in a competitive ADHD category. Lower targets discount the stock for clinical and financing risk, while higher targets model commercial success for multiple pipeline candidates. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The stock closed near $5.53 in late October 2026, with a market capitalization around $80 million and about 14.5 million shares outstanding. Its 52-week range is $3.16 to $11.89. From a price near $5.53, the $21 target implies roughly 280% upside, which is a very large move requiring a step-change in the company's fundamental value rather than a modest re-rating. The path toward such a level would depend on clinical catalysts. Cingulate generates no product revenue and reported a net loss of roughly $28.8 million over the trailing twelve months. A move toward the target would most plausibly be driven by positive Phase 3 data for CTx-1301, followed by a regulatory filing and, ultimately, commercialization. Valuation would shift from a pre-revenue, clinical-stage framework to one based on projected sales and peak-market opportunity.
What Could Support a Move Toward the Target
- Clinical pipeline progress: CTx-1301 is in Phase 3 trials for ADHD across children, adolescents, and adults; successful data would be the single most important catalyst.
- Large addressable market: ADHD is a widely treated condition with substantial existing demand, supporting a meaningful revenue opportunity if approval is secured.
- Analyst sentiment: The consensus rating is "Strong Buy," and several firms have maintained Buy ratings through 2026.
- Financial runway: Roughly $28.4 million in cash against about $6.3 million in debt, which the company has supplemented through financing arrangements.
What Could Prevent the Target From Being Reached
- Clinical and regulatory risk: Phase 3 trials can fail, and even positive data does not guarantee regulatory approval.
- Cash burn and dilution: With no revenue, the company must raise capital, which can dilute existing shareholders and pressure the share price.
- Competition: The ADHD market includes established branded and generic treatments, making market-share capture uncertain.
- Valuation risk: Pre-revenue biotech stocks are sensitive to changes in risk appetite, interest rates, and sector sentiment.
Technical Levels and Market Structure
The stock trades well below its 52-week high of $11.89 and above its 52-week low of $3.16. The 200-day moving average sits near $5.43, meaning the stock is only modestly above its longer-term trend level. A psychological and technical resistance zone exists near the prior high around $11.89; a durable break above that would be needed before the stock could begin trading toward levels implied by higher analyst targets. On the downside, the $3.16 low and the sub-$4 zone represent key support areas.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual analysts may model different time frames and probability-weighted scenarios. Investors should monitor Phase 3 trial results and any interim readouts for CTx-1301, updates on CTx-2103 (buspirone) for anxiety, quarterly cash balances and financing activity, and any analyst target revisions. Regulatory milestones and competitive developments in the ADHD market are also important. No timing should be assumed for reaching the target.
Using AI Daily Buy/Sell Signals for Biotech Names
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, news-sensitive name like Cingulate, such tools can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. Traders seeking a systematic view of daily signals can explore these AI-generated insights to complement their own research.
Final Assessment
The $21 target represents the rounded average of the analyst price targets reviewed, but the range of roughly $8 to $44 shows that analysts are far from aligned on CING's future. Reaching $21 would require a very large move of about 280% from the recent price near $5.53, hinging overwhelmingly on successful Phase 3 data for CTx-1301 and a path to commercialization. Positive clinical results and a large ADHD market support the bullish case, while cash burn, financing risk, competition, and binary clinical outcomes are the principal obstacles. Investors should watch trial readouts, financing activity, and analyst revisions before drawing conclusions, as the outcome remains uncertain and no target is guaranteed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CING in upward trend: price rose above 50-day moving average on October 26, 2026
CING moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on CING as a result. In 77 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for CING just turned positive on October 23, 2026. Looking at past instances where CING's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.
Following a +11.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where CING advanced for three days, in 191 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for CING moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 21 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for CING crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CING declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CING broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CING entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. CING’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.253) is normal, around the industry mean (3.151). P/E Ratio (-1.475) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CING’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement